



# BIOCENTURY Grand Rounds

IN COLLABORATION WITH INSIGHTS PARTNER  
MCKINSEY & COMPANY

15% off with code:  
**GRLSTN24**

Courtesy of Supporting Organization  
Life Sciences Tennessee.

## AGENDA AT-A-GLANCE

*\*Schedule subject to change*

MON 9/9		4:30 pm – 5:30 pm	<b>Heads of Pharma Research, in Conversation:</b> Biogen's Jane Grogan, Novartis' Fiona Marshall
TUES 9/10		8:00 am – 8:45 am	<b>Breakfast workshop:</b> Overcoming company formation challenges
		8:45 am – 9:00 am	Official Welcome from BioCentury
		9:00 am – 10:00 am	<b>McKinsey &amp; Company Conference Report:</b> Reimagining translation: how to unlock the next wave of breakthrough treatments
	GRAND ROUNDS I: Translational Bottlenecks	10:00 am – 10:40 am	<b>From causal biology to preclinical validation:</b> What makes the grade in 2024?
		11:10 am – 11:50 am	<b>The human first era is here:</b> Is there still value in new animal models?
		11:50 am – 12:30 pm	<b>Delivery on demand:</b> Still the elephant in the room
	GRAND ROUNDS II: The Modality Groundbreakers	1:30 pm – 2:10 pm	<b>The heyday of AAV engineering is here:</b> Will it deliver?
		2:10 PM – 2:50 PM	<b>The regenerative moment:</b> Are iPSCs poised to reshape the cell therapy toolbox?
		3:20 pm – 4:00 pm	<b>Maximizing the impact of gene editing:</b> Incremental improvements, or leaps to newer technologies?
		4:00 pm – 4:40 pm	<b>Souping up cancer cell therapies:</b> Is the juice worth the squeeze?
		4:40 pm – 5:30 pm	<b>Closing the innovation gap:</b> Partnerships for next-gen treatments
		6:00 pm – 7:00 pm	<b>Poster Spotlight Presentations:</b> At the Forefront of Translational Innovation
WED 9/11	GRAND ROUNDS III: The Human Data Revolution	9:00 am - 10:00 am	<b>Keynote Address:</b> Harvard's Greg Verdine on blowing up the small molecule paradigm
		10:00 am – 10:40 am	<b>Methods-for-purpose:</b> Analytical tools that parse signal from noise, without flattening complexity
		11:10 am – 11:50 am	<b>Data-for-purpose:</b> Go big, go deep, or go long?
	GRAND ROUNDS IV: The Disease Biology Boom	11:50 am – 12:30 pm	<b>Unlocking progress in neurology:</b> How to build the case for a new target
		12:30 pm – 1:30 pm	<b>Lunchtime Fireside Chat:</b> Vanderbilt's Robert Carnahan & Arch Venture's Lu Borio
		1:30 pm – 2:10 pm	<b>Immunity and inflammation inflection point:</b> What determines the direction from here?
		2:10 pm – 2:50 pm	<b>Closing Rapporteur Plenary:</b> What's Next For Translational Research?

Questions? Please contact:

Brian Denker, Director, Industry Events & Operations at

brian.denker@biocentury.com or visit [www.BioCenturyGrandRounds.com](http://www.BioCenturyGrandRounds.com)

**CLICK HERE TO DOWNLOAD  
THE FULL CONFERENCE BROCHURE**



IN COLLABORATION WITH INSIGHTS PARTNER  
MCKINSEY & COMPANY

## SPEAKERS

Learn from 66+ industry  
thought leaders, including:



Gonçalo Abecasis  
Regeneron



Amy Abernethy  
Former FDA




Manuel Ascano  
Vanderbilt University  
School of Medicine



Jamil Beg  
SV Health Investors



Andrew Bellinger  
Verve Therapeutics




Gwendolyn Binder  
Cabaletta Bio




Melissa Bonner  
Nvelop Therapeutics




Luciana Borio  
Arch Venture Partners




Daniel Burkhardt  
Cellarity



Robert Carnahan  
Vanderbilt University



Caroline Chung  
MD Anderson Cancer  
Center



Nancy Cox  
Vanderbilt University  
Medical Center



Aaron Esser-Kahn  
University of Chicago




Stacy Feld  
J&J Innovation




Stephen Fesik  
Vanderbilt University



Zandy Forbes  
MeiraGTx



Kevin Friedman  
Kelsonia Therapeutics



Mark Frolich  
Indapta Therapeutics



Chris Garabedian  
Perceptive Advisors



Andrei Georgescu  
Vivodyne



David Goldstein  
Actio Biosciences



Jane Grogan  
Biogen



Anika Gupta  
GV



Kristin Hege  
Former Bristol  
Myers Squibb




Colin Hill  
Aitia




Chris Hollowood  
Syncona




Sasha Huhlov  
Takeda



Carrie Jones  
Vanderbilt University



Najat Khan  
Recursion



Chaitan Khoshla  
Stanford University



Erin Krimbel  
Astellas



Sophie Kornowski  
Boston  
Pharmaceuticals



John Kuriyan  
Vanderbilt University  
School of Medicine



Guru Laxmikanthan  
Nutter



John Lepore  
ProFound  
Therapeutics



Patrick Lyden  
Keck School of  
Medicine of USC





IN COLLABORATION WITH INSIGHTS PARTNER  
MCKINSEY & COMPANY

## SPEAKERS


Learn from 66+ industry  
thought leaders, including:



Samuel Lynch  
VUMC



Marinna Madrid  
Cellino




Mathai Mammen  
FogPharma



Fiona Marshall  
Novartis



Clare Murray  
Life Edit  
Therapeutics



Gregory Newby  
Johns Hopkins  
University



Carl Novina  
Dana Farber  
Cancer Institute




Stephanie Oestreich  
Myeloma Investment  
Fund




Deborah Palestrant  
SAM Ventures



Nicole Paulk  
Siren  
Biotechnology



Jim Ray  
MD Anderson




Daniel Reich  
NIH



Jill Richardson  
Merck/MSD




Dan Roden  
Vanderbilt University  
Medical Center



Lexi Rovner  
64x Bio



Krishnendu Roy  
Vanderbilt University



Adam Savitz  
Alto Neuroscience



Florencia Segal  
MPM BioImpact



Samantha Singer  
Abata  
Therapeutics




Elizabeth Anne Stringer  
Nashville Biosciences



Paul Peter Tak  
Candel Therapeutics



Gregory Verdine  
Harvard University



Daniel von Bornstädt  
McKinsey & Company



Nikhil Wagle  
Genentech




Wei-Qi Wei  
Vanderbilt University  
Medical Center




Douglas Williams  
Sana Biotechnology



Peter Wright  
Partner  
McKinsey & Company



Guang Yang  
Partner  
McKinsey & Company



Carolyne  
Zimmermann  
SonoThera